OncoMatch/Clinical Trials/NCT07235280
Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
Is NCT07235280 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Dapagliflozin Propanediol for lung adenocarcinoma.
Treatment: Dapagliflozin Propanediol — This early phase I trial tests the safety and side effects of dapagliflozin given prior to surgery in patients with stage IA lung adenocarcinoma. Dapagliflozin is approved by the Food and Drug Administration (FDA) for the treatment of diabetes and heart failure. It is an SGLT2 inhibitor. Stage I lung adenocarcinomas express significantly higher levels of the SGLT2 protein than other stages, and research suggests that SGLT2 inhibition improves lung cancer outcomes in patients with diabetes. In this study, dapagliflozin is being used off-label, which means it is being used for a condition that it was not originally approved for by the FDA. The investigational study drug is a neoadjuvant treatment, meaning the drug is given before surgery to try and help make the surgery more effective.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MKI67 expression (testing required)
availability of biopsy tissue for Ki-67 determination
Disease stage
Required: Stage IA1, IA2, IA3 (AJCC v8)
stage Ia lung adenocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: sglt2 inhibitor
Lab requirements
Blood counts
Leukocytes ≥ 3.0 K/mm^3; Absolute neutrophil count ≥ 1.5 K/mm^3; Platelets ≥ 100 K/mm^3
Kidney function
eGFR ≥ 30 mL/min/1.73m^2
Liver function
Total bilirubin ≤ 2 mg/dl; AST ≤ 62 IU/L; ALT ≤ 70 IU/L
Leukocytes ≥ 3.0 K/mm^3; Absolute neutrophil count ≥ 1.5 K/mm^3; Platelets ≥ 100 K/mm^3; Total bilirubin ≤ 2 mg/dl; AST ≤ 62 IU/L; ALT ≤ 70 IU/L; eGFR ≥ 30 mL/min/1.73m^2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify